– USA, MA – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), a clinical-stage company developing products for treating inflammatory and immune diseases, today announced the appointment of Kenneth Gayron and Aron Shapiro to its Board of Directors, effective immediately, bringing a unique perspective, deep expertise and valuable insight to the Company.
Thomas Hancock, Dr. Morton Goldberg, and Dr. Bernard Malfroy-Camine have stepped down from the board, which is now composed of seven members.
“We are very pleased to welcome these esteemed leaders to our board as we navigate our path forward, advance our robust clinical pipeline that encompasses a broad range of therapeutic areas and build on our success to date,” said acting CEO, Dr. Franz Obermayr. “Mr. Gayron has a strong track record for enhancing operational capabilities to drive growth and Mr. Shapiro’s extensive clinical-regulatory strategy and business development experience will be invaluable assets for EyeGate’s leadership team. They are both tremendous additions to our board, and we look forward to working with them as we continue to translate organizational vision to operational excellence.”
Ken Gayron has been appointed to EyeGate’s Board of Directors as Chair of the Audit Committee.
About Ken Gayron
Ken Gayron also currently serves as CFO and EVP at Avid Technology. At Avid, he has been responsible for driving strategic growth initiatives, capital allocation, and repositioning the Company with the investment community. Before joining Avid, Mr. Gayron served as CFO and interim CEO for Numerex, where he played a significant role in the company’s acquisition by Sierra Wireless and was CFO for Osmotica Pharmaceutical Inc. Before his career in senior finance management, Mr. Gayron worked in investment banking with UBS Investment Bank and CIBC World Markets.
Mr. Gayron earned his MBA from Cornell University and his B.S. in finance from Boston College.
About Aron Shapiro
Aron Shapiro is currently SVP and Partner in the Asset Development & Partnering group at Ora, Inc. He is responsible for Ora’s strategic partnering activities where he evaluates and performs diligence on new investment opportunities. Before moving to the Asset Development & Partnering group, Mr. Shapiro was responsible for establishing and leading clinical regulatory strategy and clinical operations across several anterior and posterior segment indications for Ora’s service business in ophthalmology and was responsible for Ora’s business development and international growth strategy.
Mr. Shapiro earned his B.S. in biological chemistry from Bates College.
About EyeGate
EyeGate is a clinical-stage pharmaceutical company developing and commercializing products for treating inflammatory and immune diseases. PP-001, EyeGate’s lead clinical-stage drug product, is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of Dihydroorotate Dehydrogenase with best-in-class picomolar potency and a validated immune-modulating mechanism designed to overcome the off-target side effects and safety issues associated with DHODH inhibitors. PP-001 is being developed in multiple formulations for various indications, including ophthalmic, intravenous, and oral formulations. Also, EyeGate is developing Ocular Bandage Gel, a modified form of the natural polymer hyaluronic acid, designed to protect the ocular surface to permit re-epithelialization of the cornea and improve ocular surface integrity. OBG has unique properties that help hydrate and protect the ocular surface.
For more information: https://www.eyegatepharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.